Key result
Alternative anticoagulants, particularly direct thrombin inhibitors like argatroban and lepirudin, are preferred for managing heparin-induced thrombocytopenia in cardiovascular patients.
This review summarizes the preferred alternative anticoagulation strategies for managing heparin-induced thrombocytopenia across various cardiovascular clinical scenarios.
Answers are grounded in this paper and cite their sources.
May inform anticoagulant choice in cardiovascular HIT; extends prior reviews but leaves open need for prospective trials.
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated syndrome associated with heparin exposure, a falling platelet count and a high risk of thrombosis. Cardiovascular patients are at increased risk of HIT due to wide use of heparin in this population. Should HIT be suspected, heparin must be avoided in most situations, and anticoagulation with an alternative anticoagulant should be instituted. Preferred agents include the direct thrombin inhibitors argatroban and lepirudin, whilst bivalirudin or desirudin (other direct thrombin inhibitors) can be used in some situations. The indirect thrombin inhibitors, danaparoid and fondaparinux, can also be considered at times. These agents and their use in cardiac patients, including patients with acute coronary syndrome, percutaneous coronary interventions, acute ST elevation myocardial infarction or cardiac surgery, will be reviewed.
No takes yet. Share an insight, caveat, or question.
William Matthai (2006) conducted a review in Heparin-induced thrombocytopenia. Alternative anticoagulants (argatroban, lepirudin, bivalirudin, desirudin, danaparoid, fondaparinux) was evaluated. Alternative anticoagulants, particularly direct thrombin inhibitors like argatroban and lepirudin, are preferred for managing heparin-induced thrombocytopenia in cardiovascular patients.
Synapse has enriched 10 related papers. Consider them for comparative context: